var data={"title":"Tiotropium and olodaterol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tiotropium and olodaterol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/770053?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tiotropium-and-olodaterol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tiotropium and olodaterol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326231\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Asthma-related death:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Long-acting beta<sub>2</sub>-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in  tiotropium/olodaterol, increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of another long-acting beta<sub>2</sub>-adrenergic agonist (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol.  This finding of an increased risk of asthma-related death with salmeterol is considered a class effect of LABA, including olodaterol. The safety and efficacy of  tiotropium/olodaterol in patients with asthma have not been established. Tiotropium/olodaterol is not indicated for the treatment of asthma.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28405645\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Stiolto Respimat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48777732\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Inspiolto Respimat</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326233\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticholinergic Agent;</li>\n      <li>\n        Anticholinergic Agent, Long-Acting;</li>\n      <li>\n        Beta<sub>2</sub> Agonist;</li>\n      <li>\n        Beta<sub>2</sub>-Adrenergic Agonist, Long-Acting</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640773\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>COPD:</b> Oral inhalation: Two inhalations once daily (maximum: 2 inhalations per day)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640774\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640775\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &le;60 mL/minute: No dosage adjustment necessary; monitor closely for anticholinergic adverse effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640776\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28405646\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Aerosol Solution, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stiolto Respimat: Tiotropium 2.5 mcg and olodaterol 2.5 mcg per actuation (4 g) [contains benzalkonium chloride, edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28405644\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46519122\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Stiolto Respimat 4 g contains 60 inhalations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48823636\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol Solution, Inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Inspiolto Respimat: Tiotropium 2.5 mcg and olodaterol 2.5 mcg per actuation [contains benzalkonium chloride, edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49639349\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206756s006lbl.pdf&amp;token=tgi/3ze7+bmA5a1Zuzig874eZieANMH6JUr6F13PjQg9SojBqbpomtqaqHI4eoVTzff/gQyWI6J774X2Sd2gY2Rky4todnWGu3XxTU0BiNo=&amp;TOPIC_ID=101635\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206756s006lbl.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640778\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For oral inhalation only. Prime inhaler prior to initial use or if not used for &gt;21 days; point inhaler toward ground and actuate until aerosol cloud is seen, then repeat 3 additional times before use. If not used for &gt;3 days (but &le;21 days), actuate once before use. When dose is ready to be administered, breathe in slowly through the mouth and press the dose-release button; continue to breathe in slowly as long as possible, then hold breath for 10 seconds or for as long as comfortable. Repeat for second inhalation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326235\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic obstructive pulmonary disease: </b> Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated to treat acute deteriorations of COPD; not indicated to treat asthma (safety and effectiveness in asthma have not been established)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29120477\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&le;3%, postmarketing, and/or case reports: Angioedema, arthralgia, atrial fibrillation, blurred vision, bronchospasm, constipation, dehydration, dermal ulcer, dizziness, dysphagia, dysuria, epistaxis, gastroesophageal reflux disease, gingivitis, glaucoma, glossitis, hypersensitivity (including immediate reactions), hypertension, increased intraocular pressure, insomnia, intestinal obstruction (including paralytic ileus), joint swelling, laryngitis, oropharyngeal candidiasis, palpitations, pharyngitis, pruritus, sinusitis, skin infection, skin rash, stomatitis, supraventricular tachycardia, tachycardia, urinary retention, urinary tract infection, urticaria, voice disorder, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28326236\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of the formulation; use in the treatment of asthma without a concomitant long-term asthma control medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to atropine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for sympathomimetics is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640754\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma-related deaths: <b>[US Boxed Warning]: Long-acting beta<sub>2</sub>-agonists (LABAs) increase the risk of asthma-related deaths. The safety and efficacy of olodaterol in the treatment of asthma have not been established. In a large, randomized, placebo-controlled US clinical trial (SMART 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Tiotropium/olodaterol is not indicated for the treatment of asthma.</b> It is unknown if olodaterol increases asthma-related deaths. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use; however, current guidelines recommend the use of an inhaled corticosteroid before adding a LABA (GINA 2015; NIH/NHLBI 2007).  In a more recent multicenter, randomized, double-blinded trial, the use of salmeterol and an inhaled corticosteroid (ie, fluticasone) combined in a single inhaler in a large number of children, adolescent, and adult patients with persistent asthma (non-life threatening and stable) did not increase the risk of serious asthma-related events compared with fluticasone alone; in addition, patients receiving fluticasone/salmeterol had fewer severe asthma exacerbations compared with patients receiving fluticasone alone (Peters 2016; Stempel 2016a; Stempel 2016b). No data exist associating LABA use with an increased risk of death in patients with COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Paradoxical bronchospasm may occur with use of inhaled agents; distinguish from inadequate response, discontinue medication immediately, and institute alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness and blurred vision; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions, including urticaria, angioedema, itching, rash, bronchospasm, or anaphylaxis, have been reported. Discontinue immediately if signs/symptoms occur. Use with caution in patients with a history of hypersensitivity to atropine or its derivatives.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disorders, especially arrhythmias, coronary insufficiency, hypertension, and hypertrophic obstructive cardiomyopathy; beta-agonists may cause elevation in blood pressure and heart rate. Beta<sub>2</sub>-agonists may also produce electrocardiogram (ECG) changes (eg, T-wave flattening, QTc prolongation, ST segment depression).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Tiotropium may worsen symptoms of narrow-angle glaucoma; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; beta<sub>2</sub>-agonists may stimulate thyroid activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta<sub>2</sub>-agonists may decrease serum potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/bladder neck obstruction: Tiotropium may worsen the symptoms of prostatic hyperplasia and/or bladder neck obstruction; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; monitor closely for anticholinergic adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with seizure disorders; beta<sub>2</sub>-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; LABA: Do not use with other long-acting beta<sub>2</sub>-agonists; deaths and significant cardiovascular effects have been reported with excessive sympathomimetic use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: COPD: Do <b>not</b> use for acute bronchospastic episodes of COPD; always prescribe with an inhaled short-acting beta<sub>2</sub>-agonist to treat acute symptoms. Do not initiate in patients with significantly worsening or acutely deteriorating COPD. Do not increase the dose or frequency beyond what is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407247\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407244\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101635&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the anticholinergic effect of Tiotropium.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: May enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May enhance the adverse/toxic effect of Olodaterol. Theophylline Derivatives may enhance the hypokalemic effect of Olodaterol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640751\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640752\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination. See individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640753\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if olodaterol or tiotropium are excreted in breast milk. The manufacturer recommends that caution be exercised when administering tiotropium/olodaterol to nursing women. See individual monographs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640780\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FEV<sub>1</sub>, peak flow (or other pulmonary function studies); anticholinergic adverse reactions (patients with CrCl &le;60 mL/minute); serum potassium and glucose; blood pressure and heart rate; CNS stimulation; signs and symptoms of narrow angle glaucoma and urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for increased use of short-acting beta<sub>2</sub>-agonist inhalers (may be marker of a deteriorating condition).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640768\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tiotropium:</b> Competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M3) receptors in bronchial smooth muscle causing bronchodilation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Olodaterol:</b> Long acting beta<sub>2</sub>-receptor agonist; activates beta<sub>2</sub> airway receptors, resulting in the stimulation of intracellular adenyl cyclase and a subsequent increase in the synthesis of cyclic-3&rsquo;,5&rsquo; adenosine monophosphate (cAMP). Elevated cAMP levels induce bronchodilation by relaxation of airway smooth muscle cells. Has much greater affinity for beta<sub>2</sub>-receptors than for beta<sub>1</sub>- or beta<sub>3</sub>-receptors. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28640770\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28651464\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol solution</b> (Stiolto Respimat Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5 mcg/ACT (4 g): $441.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29044430\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Spiolto (EC);</li>\n      <li>Spiolto Respimat (AT, AU, CR, CZ, DK, DO, EE, ES, GB, GT, HK, HN, HR, HU, ID, IL, IS, JP, LT, MT, MY, NI, NL, NO, NZ, PA, PH, PL, PT, RO, SE, SG, SI, SK, SV, TH);</li>\n      <li>Vahelva Respimat (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2015. www.ginasthma.org. Updated 2015. Accessed June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inspiolto Respimat (tiotropium bromide and olodaterol) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tiotropium-and-olodaterol-drug-information/abstract-text/16424409/pubmed\" target=\"_blank\" id=\"16424409\">16424409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. <i>N Engl J Med.</i> 2016;375(9):850-860. doi: 10.1056/NEJMoa1511190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tiotropium-and-olodaterol-drug-information/abstract-text/27579635/pubmed\" target=\"_blank\" id=\"27579635\">27579635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Raphiou IH, Kral KM, et al; AUSTRI Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. <i>N Engl J Med</i>. 2016a;374(19):1822-1830. doi: 10.1056/NEJMoa1511049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tiotropium-and-olodaterol-drug-information/abstract-text/26949137/pubmed\" target=\"_blank\" id=\"26949137\">26949137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Szefler SJ, Pedersen S, et al; VESTRI Investigators. Safety of adding salmeterol to fluticasone propionate in children with asthma. <i>N Engl J Med.</i> 2016b;375(9):840-849. doi: 10.1056/NEJMoa1606356.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tiotropium-and-olodaterol-drug-information/abstract-text/27579634/pubmed\" target=\"_blank\" id=\"27579634\">27579634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stiolto Respimat (tiotropium bromide and olodaterol) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101635 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F28326231\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28405645\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48777732\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28326233\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28640773\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28640774\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28640775\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28640776\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28405646\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28405644\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46519122\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F48823636\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49639349\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28640778\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28326235\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F29120477\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28326236\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28640754\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28407247\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28407244\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28640751\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28640752\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28640753\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28640780\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28640768\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28640770\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28651464\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F29044430\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101635|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tiotropium-and-olodaterol-patient-drug-information\" class=\"drug drug_patient\">Tiotropium and olodaterol: Patient drug information</a></li></ul></div></div>","javascript":null}